SCHEMBL6001297

SCHEMBL6001297

C[C@]1(C(=O)O)CNC(=O)N1C(=O)OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.47
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
GAA P10253 1/20 0.46
MAPK1 P28482 1/20 0.46
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GLA P06280 1/20 0.41
CTRB1 P17538 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
P2RX4 Q99571 2/20 0.41
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
CYP2C19 P33261 1/20 0.40
P2RX1 P51575 1/20 0.40
P2RX3 P56373 1/20 0.40
PSEN1 P49768 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7264096 1.00 HTR2C (0.47) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL11285680 0.82 HTR2C (0.45) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL30429792 0.81 HTR2C (0.44) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL7270210 0.81 NPC1 (0.45) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL1834783 0.76 HTR2C (0.49) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL542152 0.76 HTR2C (0.49) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL542153 0.76 HTR2C (0.49) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL1532832 0.74 HTR2C (0.48) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL7245273 0.74 MEN1 (0.49) HTR2CNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL630773 0.74 MEN1 (0.49) HTR2CNPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060258726-A1 1,5-Disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases MERCK FROSST CANADA LTD. (CA) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258726-A1 1,5-Disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases PTGER4, PTGER1, PTGER2 HTR2C 574/4885NPC1 1473/4885RAB9A 1188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.